DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Macitentan
Macitentan
Endothelin System and Therapeutic Application of Endothelin Receptor
4 Tier)
Comparison of Pharmacological Activity of Macitentan and Bosentan in Preclinical Models of Systemic and Pulmonary Hypertension
Opsumit) Reference Number: CP.PHAR.194 Effective Date: 03.16 Last Review Date: 02.21 Line of Business: Medicaid Revision Log
Doctors Healthcare Plans, Inc. Is an HMO with a Medicare Contract
Opsumit, INN-Macitentan
2020 Aetna Standard Plan
Balanced Drug List Dispensing Limits
OPSUMIT (Macitentan) Is an Endothelin Receptor Antagonist
Ambrisentan (Letairis and Opsumit)
Bosentan Or Macitentan Therapy in Chronic Thromboembolic Pulmonary Hypertension?
Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
Bluecare, Bluedirect, Blueessential, Bluepartner, Blueprime and Simplyblue Formularies Quantity Limit Program Summary
Minutes of the CHMP Meeting 25-29 January 2021
1 Continue Until the Day Before the Operation, but Hold on Day of Surgery
PDL)/Non-Preferred Drug List (NPDL
Endothelin ETA Receptor Blockade, by Activating ETB Receptors, Increases Vascular Permeability and Induces Exaggerated Fluid Retention S
Distinct ETA Receptor Binding Mode of Macitentan As Determined by Site Directed Mutagenesis
Top View
Medicaid List of Covered Drugs (Formulary)
Macitentan Reduces Progression of TGF-Β1- Induced Pulmonary Fibrosis and Pulmonary Hypertension
Blue Cross and Blue Shield October 2019 Multi-Tier Basic Drug List I How to Use This List Generic Drugs Are Shown in Lower-Case Boldface Type
Compiled and Produced by the Njarðarson Group (The University of Arizona)
Self-Administered Specialty Drug List
Magellan Rx Report
Final Decisions and Reasons for Decisions by Delegates of the Secretary to the Department of Health
FEP 5 Tier Rx Drug Formulary (607) Standard Option
2021 California Student Resources Traditional 3-Tier Prescription Drug List
Macitentan, a Dual Endothelin Receptor Antagonist, In
204410Orig1s000
2021 Formulary (List of Covered Drugs)
Endothelin Receptor Antagonists (Eras) Annual Review Date: Tracleer (Bosentan) 1/21/2021 Letairis (Ambrisentan) Opsumit (Macitentan) Last Revised Date: 2/18/2021
Preferred Drug List (PDL)
Macitentan / ACT-064992 Portopulmonary Hypertension AC-055-404
Reimbursement Criteria for Frequently Requested Drugs
SAFE HANDLING of HAZARDOUS DRUGS Updated 5/22/2020
Orange Book Cumulative Supplement 7 July 2021
CVS Caremark® Value Formulary Effective As of 07/01/2021
204410Orig1s000
Macitentan for the Treatment of Pulmonary Arterial Hypertension: a Review of the Literature for the Recently Approved Endothelin Receptor Antagonist
Prior Authorization — Premium
P&T Committee Meeting Minutes GHP Family November 21
11-14 June 2018 PRAC Meeting Minutes
North Dakota Department of Human Services North Dakota Medicaid Preferred Drug List with Prior Authorization Criteria Effective
Paragraph IV Patent Certifications (PPIV)
Pulmonary Arterial Hypertension EOCCO POLICY
MACITENTAN (Opsumit®)
Ez Minutes Volume 15 Issue 2 February 2017
PUBLIC SUMMARY DOCUMENT Product: MACITENTAN, Tablet, 10Mg, Opsumit® Sponsor: Actelion Pharmaceuticals Australia Pty Ltd
The Use of Physiology-Based PK and PD Modeling in the Discovery of the Dual
A Network Meta-Analysis for Safety of Endothelin Receptor Antagonists in Pulmonary Arterial Hypertension
Opsumit) Reference Number: CP.PCH.31 Effective Date: 09.01.20 Last Review Date: 08.20 Line of Business: Commercial, HIM Revision Log
Third Quarter 2017
Endothelin Antagonists
Produced by the Njarðarson Group at the University of Arizona
Reasons for Scheduling Delegate's Interim Decisions and Invitation For
Public Assessment Report
Evidence Synthesis in Pulmonary Arterial Hypertension: a Systematic